{
      "StudyFieldsResponse": {
            "APIVrs": "1.01.05",
            "DataVrs": "2022:10:06 23:25:58.836",
            "Expression": "mesenchymal Longeveron",
            "NStudiesAvail": 430108,
            "NStudiesFound": 8,
            "MinRank": 1,
            "MaxRank": 1000,
            "NStudiesReturned": 8,
            "FieldList": [
                  "MaximumAge",
                  "MinimumAge",
                  "NCTId",
                  "NCTIdAlias",
                  "OfficialTitle",
                  "OrgClass",
                  "OrgFullName",
                  "OrgStudyId",
                  "OrgStudyIdDomain",
                  "OrgStudyIdLink",
                  "OrgStudyIdType",
                  "OtherEventAssessmentType",
                  "OtherEventNotes",
                  "OtherEventOrganSystem",
                  "OtherEventSourceVocabulary"
            ],
            "StudyFields": [
                  {
                        "Rank": 1,
                        "MaximumAge": [
                              "85 Years"
                        ],
                        "MinimumAge": [
                              "70 Years"
                        ],
                        "NCTId": [
                              "NCT03169231"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 2b, Randomized, Blinded and Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Longeveron Allogenic Human Mesenchymal Stem Cells Infusion in Patients With Aging Frailty"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "001-03"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 2,
                        "MaximumAge": [
                              "90 Years"
                        ],
                        "MinimumAge": [
                              "65 Years"
                        ],
                        "NCTId": [
                              "NCT02982915"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Effects of Intravenous Delivery of Lomecel-B (Formerly Allogenic Longeveron Human Mesenchymal Stem Cells (LMSCs)) on VaccinE-Specific Antibody Responses in Subjects With Aging Frailty"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "00-0000-03"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 3,
                        "MaximumAge": [
                              "80 Years"
                        ],
                        "MinimumAge": [
                              "50 Years"
                        ],
                        "NCTId": [
                              "NCT02600130"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase, I Prospective, Randomized, Double-Blinded, Placebo-controlled, Trial to Evaluate the Safety and Potential Efficacy of Lomecel-B Infusion Versus Placebo in Patients With Alzheimer's Disease"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "00-0000-01"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 4,
                        "MaximumAge": [
                              "1 Year"
                        ],
                        "MinimumAge": [
                              "1 Day"
                        ],
                        "NCTId": [
                              "NCT03525418"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Lomecel-B Injection in Patients With Hypoplastic Left Heart Syndrome: A Phase I/II Study (ELPIS)"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "00-0000-05"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 5,
                        "MaximumAge": [
                              "85 Years"
                        ],
                        "MinimumAge": [
                              "45 Years"
                        ],
                        "NCTId": [
                              "NCT02587572"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Efficacy of Allogeneic Human Mesenchymal Stem Cells in Patients With Metabolic Syndrome."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "00-0000-02"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 6,
                        "MaximumAge": [
                              "30 Days"
                        ],
                        "MinimumAge": [],
                        "NCTId": [
                              "NCT02398604"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "Allogeneic Human MEsenchymal Stem Cell (hMSC) Injection in Patients With Hypoplastic Left Heart Syndrome: An Open Label Pilot Study."
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "20140718"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 7,
                        "MaximumAge": [],
                        "MinimumAge": [
                              "18 Years"
                        ],
                        "NCTId": [
                              "NCT04629105"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase 1 Double-blinded, Randomized, Placebo-controlled Study for COVID-19 and Influenza Virus-Elicited Acute Respiratory Distress Syndrome (ARDS) Using Lomecel-B"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "00-006"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  },
                  {
                        "Rank": 8,
                        "MaximumAge": [
                              "95 Years"
                        ],
                        "MinimumAge": [
                              "60 Years"
                        ],
                        "NCTId": [
                              "NCT02065245"
                        ],
                        "NCTIdAlias": [],
                        "OfficialTitle": [
                              "A Phase I/II, Randomized, Blinded and Placebo-controlled Trial to Evaluate the Safety and Potential Efficacy of Allogeneic Human Mesenchymal Stem Cell Infusion in Patients With Aging Frailty"
                        ],
                        "OrgClass": [
                              "INDUSTRY"
                        ],
                        "OrgFullName": [
                              "Longeveron Inc."
                        ],
                        "OrgStudyId": [
                              "20130646"
                        ],
                        "OrgStudyIdDomain": [],
                        "OrgStudyIdLink": [],
                        "OrgStudyIdType": [],
                        "OtherEventAssessmentType": [],
                        "OtherEventNotes": [],
                        "OtherEventOrganSystem": [],
                        "OtherEventSourceVocabulary": []
                  }
            ]
      }
}